Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-CXCL8/IL-8 Antibody
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T9901A-1440 Copy Product Info
🥰Excellent
Anti-CXCL8/IL-8 Antibody is a humanized monoclonal antibody targeting the chemokine CXCL8 (Interleukin-8, IL-8). CXCL8 is a pro-inflammatory chemokine frequently overexpressed in the tumor microenvironment, which promotes tumor angiogenesis, survival, proliferation, and migration by binding to its G protein-coupled receptors, CXCR1 and CXCR2. This antibody effectively neutralizes extracellular CXCL8, blocking its interaction with CXCR1/2 and subsequently disrupting the paracrine and autocrine signaling loops driven by CXCL8. This mechanism inhibits tumor-associated vascularization and diminishes tumor cell resistance to conventional therapies, making it a critical tool for researching solid tumor progression, metastasis, and microenvironmental modulation.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $278 | Inquiry | Inquiry | |
| 5 mg | $838 | Inquiry | Inquiry | |
| 10 mg | $1,330 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Antibody Information
Storage & Solubility Information
| Description | Anti-CXCL8/IL-8 Antibody is a humanized monoclonal antibody targeting the chemokine CXCL8 (Interleukin-8, IL-8). CXCL8 is a pro-inflammatory chemokine frequently overexpressed in the tumor microenvironment, which promotes tumor angiogenesis, survival, proliferation, and migration by binding to its G protein-coupled receptors, CXCR1 and CXCR2. This antibody effectively neutralizes extracellular CXCL8, blocking its interaction with CXCR1/2 and subsequently disrupting the paracrine and autocrine signaling loops driven by CXCL8. This mechanism inhibits tumor-associated vascularization and diminishes tumor cell resistance to conventional therapies, making it a critical tool for researching solid tumor progression, metastasis, and microenvironmental modulation. |
| In vitro | Anti-CXCL8/IL-8 Antibody effectively neutralize CXCL8, blocking its binding to CXCR1/2 and inhibiting downstream Akt and MAPK signaling. This suppression reduces cancer cell survival under hypoxia and inhibits endothelial cell migration, thereby preventing the early stages of angiogenesis [1]. |
| In vivo | Systemic administration of Anti-CXCL8/IL-8 Antibody reduces microvessel density and slows solid tumor growth in animal models. By neutralizing tumor-derived IL-8, the treatment also decreases metastatic potential and enhances the efficacy of co-administered cytotoxic agents [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | CXCL8/IL-8 |
| Isotype | IgG1 |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Anti-CXCL8/IL-8 Antibody chemical structure | Anti-CXCL8/IL-8 Antibody in vivo | Anti-CXCL8/IL-8 Antibody in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.